| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): a randomised, double-blind, placebo-controlled, phase 3 trial
|
Smith, Matthew
|
|
|
20 |
3 |
p. 408-419
|
artikel
|
| 2 |
Adjuvant denosumab in postmenopausal patients with hormone receptor-positive breast cancer
|
Lippman, Marc
|
|
|
20 |
3 |
p. 312-313
|
artikel
|
| 3 |
Adjuvant denosumab in postmenopausal patients with hormone receptor-positive breast cancer (ABCSG-18): disease-free survival results from a randomised, double-blind, placebo-controlled, phase 3 trial
|
Gnant, Michael
|
|
|
20 |
3 |
p. 339-351
|
artikel
|
| 4 |
Axitinib combination therapies versus sunitinib for renal cell carcinoma
|
Stirrups, Robert
|
|
|
20 |
3 |
p. e141
|
artikel
|
| 5 |
Chimney-sweeps' cancer—early proof of environmentally driven tumourigenicity
|
Benmoussa, Nadia
|
|
|
20 |
3 |
p. 338
|
artikel
|
| 6 |
Combination or single-agent chemotherapy as adjuvant treatment for pancreatic cancer?
|
Conroy, Thierry
|
|
|
20 |
3 |
p. 336-337
|
artikel
|
| 7 |
Combination therapies in prostate cancer: proceed with caution
|
Spratt, Daniel E
|
|
|
20 |
3 |
p. 321-323
|
artikel
|
| 8 |
Comparative features and outcomes between paediatric T-cell and B-cell acute lymphoblastic leukaemia
|
Teachey, David T
|
|
|
20 |
3 |
p. e142-e154
|
artikel
|
| 9 |
Conservative management of adnexal masses
|
May, Taymaa
|
|
|
20 |
3 |
p. 326-327
|
artikel
|
| 10 |
Correction to Lancet Oncol 2019; 20: 239–53
|
|
|
|
20 |
3 |
p. e132
|
artikel
|
| 11 |
Correction to Lancet Oncol 2019; 20: 361–70
|
|
|
|
20 |
3 |
p. e132
|
artikel
|
| 12 |
Darolutamide for non-metastatic, castration-resistant prostate cancer
|
Burki, Talha
|
|
|
20 |
3 |
p. e139
|
artikel
|
| 13 |
Deep convolutional neural network models for the diagnosis of thyroid cancer
|
Hu, Dan
|
|
|
20 |
3 |
p. e129
|
artikel
|
| 14 |
Deep convolutional neural network models for the diagnosis of thyroid cancer
|
Ha, Eun Ju
|
|
|
20 |
3 |
p. e130
|
artikel
|
| 15 |
Deep convolutional neural network models for the diagnosis of thyroid cancer – Authors' reply
|
Li, Xiangchun
|
|
|
20 |
3 |
p. e131
|
artikel
|
| 16 |
Disease-free survival as a surrogate for overall survival in patients with HER2-positive, early breast cancer in trials of adjuvant trastuzumab for up to 1 year: a systematic review and meta-analysis
|
Saad, Everardo D
|
|
|
20 |
3 |
p. 361-370
|
artikel
|
| 17 |
Duvelisib in indolent non-Hodgkin lymphoma
|
Das, Manjulika
|
|
|
20 |
3 |
p. e138
|
artikel
|
| 18 |
E-cigarettes and smoking cessation
|
Das, Manjulika
|
|
|
20 |
3 |
p. e136
|
artikel
|
| 19 |
Endpoint selection in HER2-positive early breast cancer
|
Amir, Eitan
|
|
|
20 |
3 |
p. 315-316
|
artikel
|
| 20 |
Female representation among US National Comprehensive Cancer Network guideline panel members
|
Green, Angela K
|
|
|
20 |
3 |
p. 327-329
|
artikel
|
| 21 |
GAS agents limit pazopanib activity in soft-tissue sarcoma
|
Gourd, Elizabeth
|
|
|
20 |
3 |
p. e140
|
artikel
|
| 22 |
Gastric cancer surgery: the importance of technique and not only the extent of lymph node dissection
|
Yang, Han-Kwang
|
|
|
20 |
3 |
p. 329-331
|
artikel
|
| 23 |
Global elimination of cervical cancer as a public health problem
|
Brisson, Marc
|
|
|
20 |
3 |
p. 319-321
|
artikel
|
| 24 |
Good outcomes for patients with classical Hodgkin lymphoma
|
Gourd, Elizabeth
|
|
|
20 |
3 |
p. e137
|
artikel
|
| 25 |
Hairy cell leukaemia mimicking multiple myeloma
|
Notarfranchi, Laura
|
|
|
20 |
3 |
p. e187
|
artikel
|
| 26 |
Hypofractionated radiotherapy after mastectomy: a new frontier
|
Jagsi, Reshma
|
|
|
20 |
3 |
p. 313-315
|
artikel
|
| 27 |
Hypofractionated versus conventional fractionated postmastectomy radiotherapy for patients with high-risk breast cancer: a randomised, non-inferiority, open-label, phase 3 trial
|
Wang, Shu-Lian
|
|
|
20 |
3 |
p. 352-360
|
artikel
|
| 28 |
Immunotherapy and targeted therapy combinations in metastatic breast cancer
|
Esteva, Francisco J
|
|
|
20 |
3 |
p. e175-e186
|
artikel
|
| 29 |
Impact of scaled up human papillomavirus vaccination and cervical screening and the potential for global elimination of cervical cancer in 181 countries, 2020–99: a modelling study
|
Simms, Kate T
|
|
|
20 |
3 |
p. 394-407
|
artikel
|
| 30 |
Improving the outcomes of checkpoint inhibitors in breast cancer
|
Peoples, George E
|
|
|
20 |
3 |
p. 316-318
|
artikel
|
| 31 |
Links between think tanks and the tobacco industry
|
Burki, Talha Khan
|
|
|
20 |
3 |
p. e133
|
artikel
|
| 32 |
Management of vertebral radiotherapy dose in paediatric patients with cancer: consensus recommendations from the SIOPE radiotherapy working group
|
Hoeben, Bianca A
|
|
|
20 |
3 |
p. e155-e166
|
artikel
|
| 33 |
Meta-analysis of penile cancer: conceptual interpretations
|
Jayaraj, Rama
|
|
|
20 |
3 |
p. e125
|
artikel
|
| 34 |
Meta-analysis of penile cancer: conceptual interpretations – Authors' reply
|
Albieri, Vanna
|
|
|
20 |
3 |
p. e126
|
artikel
|
| 35 |
No clear role for angiogenesis inhibitors in first-line therapy for stomach cancer
|
Cats, Annemieke
|
|
|
20 |
3 |
p. 323-324
|
artikel
|
| 36 |
Pazopanib in the treatment of advanced solitary fibrous tumour
|
Tu, Chao
|
|
|
20 |
3 |
p. e127
|
artikel
|
| 37 |
Pazopanib in the treatment of advanced solitary fibrous tumour – Authors' reply
|
Martin-Broto, Javier
|
|
|
20 |
3 |
p. e128
|
artikel
|
| 38 |
Pembrolizumab plus trastuzumab in trastuzumab-resistant, advanced, HER2-positive breast cancer (PANACEA): a single-arm, multicentre, phase 1b–2 trial
|
Loi, Sherene
|
|
|
20 |
3 |
p. 371-382
|
artikel
|
| 39 |
Prevention, treatment, and profit: an unsustainable alliance
|
The Lancet Oncology,
|
|
|
20 |
3 |
p. 311
|
artikel
|
| 40 |
Quality of life in men living with advanced and localised prostate cancer in the UK: a population-based study
|
Downing, Amy
|
|
|
20 |
3 |
p. 436-447
|
artikel
|
| 41 |
Quality of life in men with prostate cancer
|
Saad, Fred
|
|
|
20 |
3 |
p. 325-326
|
artikel
|
| 42 |
Ramucirumab with cisplatin and fluoropyrimidine as first-line therapy in patients with metastatic gastric or junctional adenocarcinoma (RAINFALL): a double-blind, randomised, placebo-controlled, phase 3 trial
|
Fuchs, Charles S
|
|
|
20 |
3 |
p. 420-435
|
artikel
|
| 43 |
Risk of complications in patients with conservatively managed ovarian tumours (IOTA5): a 2-year interim analysis of a multicentre, prospective, cohort study
|
Froyman, Wouter
|
|
|
20 |
3 |
p. 448-458
|
artikel
|
| 44 |
Symptoms associated with risk of laryngeal cancer
|
Burki, Talha Khan
|
|
|
20 |
3 |
p. e135
|
artikel
|
| 45 |
Targeting tissue factor in advanced solid tumours
|
Davis, Elizabeth J
|
|
|
20 |
3 |
p. 318-319
|
artikel
|
| 46 |
The extent of surgery for stage III melanoma: how much is appropriate?
|
Franke, Viola
|
|
|
20 |
3 |
p. e167-e174
|
artikel
|
| 47 |
Tisotumab vedotin in patients with advanced or metastatic solid tumours (InnovaTV 201): a first-in-human, multicentre, phase 1–2 trial
|
de Bono, Johann S
|
|
|
20 |
3 |
p. 383-393
|
artikel
|
| 48 |
Towards a standard of care in oncology for transgender patients
|
Burns, Zackory T
|
|
|
20 |
3 |
p. 331-333
|
artikel
|
| 49 |
UK health tourism for private cancer care
|
Burki, Talha Khan
|
|
|
20 |
3 |
p. 334
|
artikel
|
| 50 |
UK universities lack transparency on clinical trials
|
Gourd, Elizabeth
|
|
|
20 |
3 |
p. e134
|
artikel
|
| 51 |
What a picture can tell you about surviving breast cancer
|
Catania, Gianluca
|
|
|
20 |
3 |
p. 335
|
artikel
|
Tijdschrift beschrijving